Supplements for eye health
There is one trial-validated eye supplement formula in adults — AREDS2 for specific stages of age-related macular degeneration. Everything else is much weaker.
The eye-health supplement plan, in order of clinical importance
Step 1: Get an eye exam
The AREDS2 formula is indicated for specific stages of AMD (typically intermediate AMD, or advanced AMD in one eye). If you don't have AMD, the formula doesn't have the same evidence base — taking it preventively in low-risk adults has not shown clear benefit. Establish your eye-health baseline with an ophthalmologist or optometrist before reaching for AREDS2 doses.
Step 2: If you have intermediate AMD or advanced AMD in one eye — AREDS2
AREDS2 formula daily: vitamin C 500 mg, vitamin E 400 IU, lutein 10 mg, zeaxanthin 2 mg, zinc 80 mg (or 25 mg in some patients to reduce GI side effects), copper 2 mg. AREDS2 RCT showed ~25% reduction in progression to advanced AMD over 5 years. Effect is real but modest. Note: AREDS2 removed beta-carotene from the original AREDS formula because of lung cancer risk in smokers; the lutein/zeaxanthin substitute was the replacement.
Step 3: If you have dry eye disease — omega-3 EPA/DHA
Omega-3 EPA+DHA 1–2 g/day for 12 weeks. Meta-analyses (Giannaccare 2019, Liu 2014) support omega-3 in dry eye, particularly evaporative dry eye and meibomian gland dysfunction. The DREAM trial in 2018 was negative at 12 months — but this may have related to placebo (olive oil) and population selection. Reasonable trial in most dry eye patients alongside artificial tears and lid hygiene.
Step 4: Dietary backup if you don't eat the right foods
If you eat leafy greens (kale, spinach, collards) 3+ times/week, oily fish 2+ times/week, eggs (a meaningful zeaxanthin source) regularly, and citrus or peppers, you're getting eye-protective nutrients from food. If you don't, lutein + zeaxanthin 10 mg + 2 mg and omega-3 1 g/day are reasonable backstops. Whole food is cheaper and broader-benefit than the supplement.
Step 5: Lifestyle factors that matter more than any supplement
UV-blocking sunglasses outdoors (cataract and AMD risk reduction). Smoking cessation (smoking doubles AMD risk and accelerates cataract). Cardiovascular risk management (the macula is a vascular end-organ). Glycemic control in diabetes (diabetic retinopathy is the leading cause of preventable blindness in working-age adults). The 20-20-20 rule (every 20 minutes of close work, look 20 feet away for 20 seconds) for digital eye strain.
If you have specific eye conditions
Macular degeneration: see our AMD protocol. Dry eye: dry eye protocol. Cataract: cataract prevention. Glaucoma: glaucoma adjunct.
What to skip
- "Blue light protection" supplements — typically marketing lutein/zeaxanthin as "blue light blockers." Some basis to the macular pigment / blue light filtering, but the supplement claim is overhyped compared to wearing tinted glasses or reducing screen time.
- "Vision restoration" combination products — established refractive errors don't reverse with supplements. Cataracts don't either.
- N-acetyl carnosine eye drops marketed for cataract reversal — not supported by rigorous trials.
- High-dose beta-carotene as standalone supplement in smokers — increased lung cancer risk (CARET, ATBC trials). This is why AREDS2 replaced beta-carotene with lutein/zeaxanthin.
- Mega-dose vitamin C (1+ g/day chronically) — observational signal of increased cataract risk in long-term users; no eye-specific benefit at megadoses.
- "Eye gummy vitamins" with sub-therapeutic ingredient amounts — typically a homeopathic-dose lutein with added sugar.
- Saffron at "vision-restoring" doses for AMD — small trials show signal but evidence is preliminary and doses/products vary widely.
- "Floater dissolving" supplements — vitreous floaters don't dissolve with any supplement.
Sources
- Age-Related Eye Disease Study 2 (AREDS2) Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the AREDS2 randomized clinical trial. JAMA. 2013;309(19):2005–2015. PMID: 23644932
- Chew EY, et al. Long-term outcomes of adding lutein/zeaxanthin and omega-3 fatty acids to the AREDS supplements on AMD progression: AREDS2 report 28. JAMA Ophthalmol. 2022;140(7):692–698. PMID: 35588041
- Giannaccare G, et al. Efficacy of omega-3 fatty acid supplementation for treatment of dry eye disease: a meta-analysis. Cornea. 2019;38(5):565–573. PMID: 30702470
- Dry Eye Assessment and Management Study Research Group. n-3 fatty acid supplementation for the treatment of dry eye disease (DREAM). N Engl J Med. 2018;378(18):1681–1690. PMID: 29652551
- Mathew MC, et al. Antioxidant vitamin supplementation for preventing and slowing the progression of age-related cataract. Cochrane Database Syst Rev. 2012;(6):CD004567. PMID: 22696344
- Christen WG, et al. Age-related cataract in a randomized trial of vitamins E and C in men. Arch Ophthalmol. 2010;128(11):1397–1405. PMID: 21060040